Neurosense Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. The company was founded in 2017 and is headquartered in Israel.
Neurosense's lead product candidate is PrimeC, a proprietary drug-device combination that is being developed for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. PrimeC is designed to deliver a high dose of the drug clemastine to the spinal cord, where it can block the activity of a protein that is thought to play a role in the progression of ALS.
Neurosense is currently conducting a Phase 2b clinical trial of PrimeC in patients with ALS. The company has also initiated a Phase 1 clinical trial of PrimeC in patients with Parkinson's disease.
Neurosense has raised over $100 million in funding from a number of investors, including OrbiMed Advisors, RA Capital Management, and Johnson & Johnson Innovation. The company is well-funded and has a strong management team.